{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:33:26Z","timestamp":1793658806908,"version":"4.5.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100015969","name":"Fay Fuller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.euroneuro.2021.07.092","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T22:51:29Z","timestamp":1628376689000},"page":"34-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial"],"prefix":"10.1016","volume":"53","author":[{"given":"Bernhard T.","family":"Baune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Louise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Oliver","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie T.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Fourrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2021.07.092_bib0001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0002","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/da.20589","article-title":"Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial","volume":"26","author":"Akhondzadeh","year":"2009","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0003","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1517\/14740338.2015.1046836","article-title":"Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder","volume":"14","author":"Al-Sukhni","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.physbeh.2019.05.006","article-title":"The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials","volume":"207","author":"Allison","year":"2019","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0005","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19f12907","article-title":"Anti-inflammatory treatments for depression: perspectives on how to read a meta-analysis critically","volume":"80","author":"Andrade","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fpsyt.2019.00458","article-title":"Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in mdd patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium","volume":"10","author":"Arteaga-Henriquez","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jnnp-2019-320912","article-title":"Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials","volume":"91","author":"Bai","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0008","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/7854_2016_19","article-title":"Are non-steroidal anti-inflammatory drugs clinically suitable for the treatment of symptoms in depression-associated inflammation?","volume":"31","author":"Baune","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0009","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jad.2017.12.056","article-title":"The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study","volume":"229","author":"Baune","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2215-0366(20)30155-3","article-title":"Anti-inflammatory treatment of bipolar depression: promise and disappointment","volume":"7","author":"Berk","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0011","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1741-7015-11-200","article-title":"So depression is an inflammatory disease, but where does the inflammation come from?","volume":"11","author":"Berk","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euroneuro.2020.11.016","article-title":"Brain-immune crosstalk in the treatment of major depressive disorder","volume":"45","author":"Branchi","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0013","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11126-019-09707-3","article-title":"Minocycline for depressive symptoms: a meta-analysis of randomized, double-blinded, placebo-controlled trials","volume":"91","author":"Cai","year":"2020","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pharmthera.2011.01.014","article-title":"Immune system to brain signaling: neuropsychopharmacological implications","volume":"130","author":"Capuron","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(20)30036-5","article-title":"Treatment outcomes for depression: challenges and opportunities","author":"Cuijpers","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2019.06.015","article-title":"Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue","volume":"81","author":"Enache","year":"2019","journal-title":"Brain Behav. Immunity"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pnpbp.2014.10.003","article-title":"A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression","volume":"57","author":"Eyre","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0019","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-0042-103159","article-title":"Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression","volume":"49","author":"Eyre","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pnpbp.2014.06.011","article-title":"A phase-specific neuroimmune model of clinical depression","volume":"54","author":"Eyre","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0021","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/hup.2401","article-title":"Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"29","author":"Faridhosseini","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbi.2019.11.002","article-title":"Rapeseed oil fortified with micronutrients improves cognitive alterations associated with metabolic syndrome","volume":"84","author":"Fourrier","year":"2020","journal-title":"Brain Behav. Immunity"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13063-018-2829-7","article-title":"Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo","volume":"19","author":"Fourrier","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S1092852918001499","article-title":"Neuroinflammation and cognition across psychiatric conditions","volume":"24","author":"Fourrier","year":"2019","journal-title":"CNS Spectr"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pnpbp.2017.03.016","article-title":"The anti-inflammatory mechanism of antidepressants \u2013 SSRIs, SNRIs","volume":"80","author":"Ga\u0142ecki","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0026","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0027","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2215-0366(20)30138-3","article-title":"Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial","volume":"7","author":"Husain","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0028","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S2215-0366(20)30193-0","article-title":"Assessing adjunctive treatments for bipolar depression","volume":"7","author":"Husain","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0029","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/0269881117725711","article-title":"Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis","volume":"31","author":"Husain","year":"2017","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/13811118.2017.1334610","article-title":"Use of the Columbia-Suicide Severity Rating Scale (C-SSRS) to classify suicidal behaviors","volume":"22","author":"Interian","year":"2018","journal-title":"Arch. Suicide Res."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0031","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jad.2005.03.012","article-title":"Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity","volume":"87","author":"Kaestner","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0032","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mp.2016.167","article-title":"Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions","volume":"23","author":"Kappelmann","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0033","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12472","article-title":"Cognitive deficits in the THINC-integrated tool (THINC-it) are associated with psychosocial dysfunction in patients with major depressive disorder","volume":"80","author":"Knight","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113906","article-title":"Psychological training to improve psychosocial function in patients with major depressive disorder: a randomised clinical trial","volume":"300","author":"Knight","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0035","article-title":"Vortioxetine for depression in adults","volume":"7","author":"Koesters","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0036","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/acps.13016","article-title":"Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials","volume":"139","author":"K\u00f6hler-Forsberg","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0037","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/acps.12698","article-title":"Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies","volume":"135","author":"K\u00f6hler","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0038","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","article-title":"Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials","volume":"71","author":"K\u00f6hler","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0039","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1017\/S0033291712000141","article-title":"Stability and transitions of depressive subtypes over a 2-year follow-up","volume":"42","author":"Lamers","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41380-019-0474-5","article-title":"Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0041","first-page":"891","article-title":"A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study","volume":"14","author":"Majd","year":"2015","journal-title":"Iran J. Pharm. Res."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0042","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4088\/JCP.16m11329","article-title":"The THINC-Integrated Tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder","volume":"78","author":"McIntyre","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0043","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S2215-0366(20)30357-6","article-title":"Trial failures of anti-inflammatory drugs in depression","volume":"7","author":"Miller","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0044","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ijnp\/pyaa092","article-title":"Clinical switching strategies of various antidepressants to vortioxetine in the PREDDICT trial","volume":"24","author":"Mills","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0046","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"Muller","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0047","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pnpbp.2013.09.006","article-title":"Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis","volume":"48","author":"Na","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0048","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1503\/jpn.180208","article-title":"Large-scale evidence for an association between low-grade peripheral inflammation and brain structural alterations in major depression in the BiDirect study","volume":"44","author":"Opel","year":"2019","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0049","first-page":"891","article-title":"Pharmacological treatment of cognitive symptoms in major depressive disorder","volume":"16","author":"Pan","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0051","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0052","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1745-0179-3-5","article-title":"Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder","volume":"3","author":"Rosa","year":"2007","journal-title":"Clin. Pract. Epidemiol. Ment. Health"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0053","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jad.2017.10.042","article-title":"Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials","volume":"227","author":"Rosenblat","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0054","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2021.07.092_bib0055","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115760","article-title":"Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1\/2 inhibitors in human monocytes","volume":"28","author":"Talmon","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0057","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bph.14074","article-title":"Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes\/macrophages","volume":"175","author":"Talmon","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0058","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jad.2020.03.022","article-title":"Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression","volume":"268","author":"Tomaz","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0059","doi-asserted-by":"crossref","first-page":"e1113","DOI":"10.4088\/JCP.13r08800","article-title":"Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis","volume":"75","author":"Udina","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0061","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","article-title":"Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders","volume":"25","author":"Wittenberg","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0062","unstructured":"World Health Organization, 2020. Depression, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"10.1016\/j.euroneuro.2021.07.092_bib0063","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpsychores.2018.05.008","article-title":"Interleukin, tumor necrosis factor-\u03b1 and C-reactive protein profiles in melancholic and non-melancholic depression: a systematic review","volume":"111","author":"Yang","year":"2018","journal-title":"J. Psychosom. Res."}],"updated-by":[{"DOI":"10.1016\/j.euroneuro.2022.09.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000}}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21003746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21003746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:39:45Z","timestamp":1668695985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X21003746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":63,"alternative-id":["S0924977X21003746"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.07.092","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.07.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}